EPElena B. Pasquale

Elena B. Pasquale

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Elena B. Pasquale has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Design and Synthesis of Potent Bivalent Peptide Agonists Targeting the EphA2 Receptor

    by Srinivas Duggineni, Sayantan Mitra, Ilaria Lamberto, Xiaofeng Han, Yan Xu, Jing An, Elena B. Pasquale, Ziwei Huang

    Designing potent and selective peptides and small molecules that target Eph receptor tyrosine kinases remains a challenge, and new strategies are needed for developing novel and potent ligands for these receptors. In this study, we performed a structure–activity relationship study of a previously identified 12 amino acid-long peptide, SWL, by alanine scanning to identify residues important for receptor binding. To further enhance and optimize the receptor binding affinity of the SWL peptide, we applied the concept of bivalent ligand design to synthesize several SWL-derived dimeric peptides as novel ligands capable of binding simultaneously to two EphA2 receptor molecules. The dimeric peptides possess higher receptor binding affinity than the original monomeric SWL peptide, consistent with bivalent binding. The most potent dimeric peptide, a SWL dimer with a six-carbon linker, has about 13-fold increased potency as compared to SWL. Furthermore, similar to SWL, the dimeric peptide is an agonist and can promote EphA2 tyrosine phosphorylation (activation) in cultured cells.


  • Crosstalk of the EphA2 receptor with a serine/threonine phosphatase suppresses the Akt-mTORC1 pathway in cancer cells

    by Nai-Ying Yang, Carlos Fernandez, Melanie Richter, Zhan Xiao, Fatima Valencia, David A. Tice, Elena B. Pasquale


  • The SH2 domain protein Shep1 regulates the in vivo signaling function of the scaffolding protein Cas

    by Séverine Roselli, Yann Wallez, Lei Wang, Virginie Vervoort, Elena B. Pasquale


  • Open Access

    The Src Homology 2 Domain Protein Shep1 Plays an Important Role in the Penetration of Olfactory Sensory Axons into the Forebrain

    by Lei Wang, Virginie Vervoort, Yann Wallez, Nathalie Coré, Harold Cremer, Elena B. Pasquale

    Shep1 is a multidomain signaling protein that forms a complex with Cas, a key scaffolding component of integrin signaling pathways, to promote the migration of non-neuronal cells. However, the physiological function of Shep1 in the nervous system remains unknown. Interestingly, we found that Shep1 and Cas are both concentrated in the axons of developing olfactory sensory neurons (OSNs). These neurons extend their axons from the olfactory epithelium to the olfactory bulb located at the anterior tip of the forebrain. However, in developing Shep1 knock-out mice, we did not detect penetration of OSN axons across the pial basement membrane surrounding the olfactory bulb, suggesting that Shep1 function is important for the establishment of OSN connections with the olfactory bulb. Interestingly, we observed reduced levels of Cas tyrosine phosphorylation in OSN axons of Shep1 knock-out mice, suggesting compromised Cas signaling function. Indeed, when embedded in a three-dimensional gel of basement membrane proteins, explants from Shep1 knock-out olfactory epithelium extend neuronal processes less efficiently than explants from control epithelium. Furthermore, ectopic expression of Shep1 in non-neuronal cells promotes cell migration through a collagen gel. Later in development, loss of Shep1 function also causes a marked reduction in olfactory bulb size and disruption of bulb lamination, which may be primarily attributable to the defective innervation. The greatly reduced OSN connections and hypoplasia of the olfactory bulb, likely resulting in anosmia, are reminiscent of the symptoms of Kallmann syndrome, a human developmental disease that can be caused by mutations in a growing number of genes.


  • Pericyte deficiencies lead to aberrant tumor vascularizaton in the brain of the NG2 null mouse

    by Feng-Ju Huang, Weon-Kyoo You, Paolo Bonaldo, Thomas N. Seyfried, Elena B. Pasquale, William B. Stallcup


  • Structure−Activity Relationship Analysis of Peptides Targeting the EphA2 Receptor

    by Sayantan Mitra, Srinivas Duggineni, Mitchell Koolpe, Xuejun Zhu, Ziwei Huang, Elena B. Pasquale

    The EphA2 receptor tyrosine kinase has emerged as a promising new therapeutic target in cancer because of its high level of expression in tumors. EphA2-specific antibodies have been used to deliver drugs and toxins to tumor cells, leading to inhibition of tumor growth and metastatic dissemination. We previously identified two related peptides, YSA and SWL, that selectively bind to the ligand-binding domain of EphA2 but not other Eph receptors and could therefore be useful as selective targeting agents. Here we characterize the two peptides and a series of derivatives. On the basis of systematic amino acid replacements, only five YSA residues appear to be critical for high-affinity receptor binding. Furthermore, a peptide comprising only the first five residues of YSA retains selectivity for EphA2. Similar to ephrin-A1, the physiological ligand for EphA2, both YSA and SWL activate EphA2 and inhibit downstream oncogenic signaling pathways in PC3 cancer cells. The two peptides and derivatives are quite stable in conditioned cell culture medium and show promise for delivering drugs and imaging agents to EphA2-expressing tumors.


  • Top Cited Papers

    Eph receptors and ephrins in cancer: bidirectional signalling and beyond

    by Elena B. Pasquale

    The Eph receptors are the largest family of receptor tyrosine kinases. They bind glycosylphosphatidylinositol (GPI)-linked and transmembrane ephrin ligands, generating bidirectional signals at sites of cell–cell contact. Eph receptors and/or ephrins are widely expressed in cancer cells and tumour stroma, but they can be downregulated at advanced cancer stages. Often Eph receptor and ephrin levels are discordantly regulated. In addition to changes in expression levels, Eph receptor mutations are also likely to have a role in cancer pathogenesis. In many cellular contexts, Eph bidirectional signalling promotes an epithelial phenotype and suppresses cancer cell–substrate adhesion, migration, invasion and growth. Consistent with this, Eph receptor signalling seems to be low in many cancer cells owing to an imbalance of Eph and ephrin expression or the inability of receptor and ligand to interact effectively. Eph receptors and ephrins can also promote cancer progression through poorly understood mechanisms that do not involve reciprocal association but rather depend on crosstalk with oncogenic signalling pathways. In addition, Eph bidirectional signals promote tumour angiogenesis. Eph receptors and ephrins are promising new therapeutic targets in cancer, and many Eph-based approaches show promise for prognosis and therapy.


  • Open Access

    Structural Characterization of the EphA4-Ephrin-B2 Complex Reveals New Features Enabling Eph-Ephrin Binding Promiscuity

    by Haina Qin, Roberta Noberini, Xuelu Huan, Jiahai Shi, Elena B. Pasquale, Jianxing Song


  • Open Access

    Ephrin-independent regulation of cell substrate adhesion by the EphB4 receptor

    by Nicole K. Noren, Nai-Ying Yang, Morgan Silldorff, Ravi Mutyala, Elena B. Pasquale

    Receptor tyrosine kinases of the Eph family become tyrosine phosphorylated and initiate signalling events upon binding of their ligands, the ephrins. Eph receptors such as EphA2 and EphB4 are highly expressed but poorly tyrosine phosphorylated in many types of cancer cells, suggesting a limited interaction with ephrin ligands. Nevertheless, decreasing the expression of these receptors affects the malignant properties of cancer cells, suggesting that Eph receptors may influence cancer cells independently of ephrin stimulation. Ligand-independent activities of Eph receptors in cancer, however, have not been demonstrated. By using siRNA (small interfering RNA) to downregulate EphB4 in MCF7 and MDA-MB-435 cancer cells, we found that EphB4 inhibits integrin-mediated cell substrate adhesion, spreading and migration, and reduces β1-integrin protein levels. Low expression of the EphB4 preferred ligand, ephrin-B2, and minimal contact between cells in these assays suggest that cell contact-dependent stimulation of EphB4 by the transmembrane ephrin-B2 ligand does not play a role in these effects. Indeed, inhibitors of ephrin-B2 binding to endogenous EphB4 did not influence cell substrate adhesion. Increasing EphB4 expression by transient transfection inhibited cell substrate adhesion, and this effect was also independent of ephrin stimulation because it was not affected by single amino acid mutations in EphB4 that impair ephrin binding. The overexpressed EphB4 was tyrosine phosphorylated, and we found that EphB4 kinase activity is important for inhibition of integrin-mediated adhesion, although several EphB4 tyrosine phosphorylation sites are dispensable. These findings demonstrate that EphB4 can affect cancer cell behaviour in an ephrin-independent manner.


  • Glial ephrin-A3 regulates hippocampal dendritic spine morphology and glutamate transport

    by Maria A. Carmona, Keith K. Murai, Lei Wang, Amanda J. Roberts, Elena B. Pasquale

    Increasing evidence indicates the importance of neuron-glia communication for synaptic function, but the mechanisms involved are not fully understood. We reported that the EphA4 receptor tyrosine kinase is in dendritic spines of pyramidal neurons of the adult hippocampus and regulates spine morphology. We now show that the ephrin-A3 ligand, which is located in the perisynaptic processes of astrocytes, is essential for maintaining EphA4 activation and normal spine morphology in vivo. Ephrin-A3-knockout mice have spine irregularities similar to those observed in EphA4-knockout mice. Remarkably, loss of ephrin-A3 or EphA4 increases the expression of glial glutamate transporters. Consistent with this, glutamate transport is elevated in ephrin-A3-null hippocampal slices whereas Eph-dependent stimulation of ephrin-A3 signaling inhibits glutamate transport. Furthermore, some forms of hippocampus-dependent learning are impaired in the ephrin-A3-knockout mice. Our results suggest that the interaction between neuronal EphA4 and glial ephrin-A3 bidirectionally controls synapse morphology and glial glutamate transport, ultimately regulating hippocampal function.